替瑞奇珠单抗 (Ilumya, Ilumetri)

概览

Tildrakizumab is an interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.

作用机制

This drug selectively binds interleukin (IL)-23 p19 subunit of cytokine IL-23 and neutralizes its function IL-23 regulates Th17 cells and is a powerful activator of keratinocyte proliferation . Targeting IL-23p19 alone has been found to be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis. Upon administration, downregulation of Th17 and Th22 cell responses occur . IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines .

适应症

Moderate-severe plaque psoriasis , .

• Moderate to Severe Plaque Psoriasis